Do Overweight Status and Obesity Affect Progression to ESKD in Autosomal Dominant Polycystic Kidney Disease?
作者信息
Carriazo Sol, Pei York
机构信息
Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada.
出版信息
Clin J Am Soc Nephrol. 2025 Apr 1;20(4):471-473. doi: 10.2215/CJN.0000000690. Epub 2025 Mar 13.
Abstract
摘要
相似文献
1
Do Overweight Status and Obesity Affect Progression to ESKD in Autosomal Dominant Polycystic Kidney Disease?超重和肥胖状态是否会影响常染色体显性多囊肾病进展为终末期肾病？
Clin J Am Soc Nephrol. 2025 Apr 1;20(4):471-473. doi: 10.2215/CJN.0000000690. Epub 2025 Mar 13.
3
Interventions for preventing the progression of autosomal dominant polycystic kidney disease.用于预防常染色体显性遗传性多囊肾病进展的干预措施。
Cochrane Database Syst Rev. 2024 Oct 2;10(10):CD010294. doi: 10.1002/14651858.CD010294.pub3.
4
Overweight Status, Obesity, and Progression to ESKD in Patients with Autosomal Dominant Polycystic Kidney Disease.常染色体显性多囊肾病患者的超重状态、肥胖与终末期肾病进展
Clin J Am Soc Nephrol. 2025 Apr 1;20(4):520-528. doi: 10.2215/CJN.0000000640. Epub 2025 Feb 19.
5
Clinical characteristics and outcomes of kidney transplantation in autosomal dominant polycystic kidney disease patients.常染色体显性多囊肾病患者肾移植的临床特征及结局
J Nephrol. 2024 Nov 4. doi: 10.1007/s40620-024-02101-8.
6
Vascular transcriptional and metabolic changes precede progressive intra-renal microvascular rarefaction in autosomal dominant polycystic kidney disease.在常染色体显性遗传性多囊肾病中，血管转录和代谢变化先于进行性肾内微血管稀疏。
bioRxiv. 2025 Jul 4:2025.06.30.662386. doi: 10.1101/2025.06.30.662386.
7
Volume Reduction in Enlarged Kidneys in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Prior to Renal Transplant with Transcatheter Arterial Embolization (TAE): A Systematic Review and Meta-Analysis.肾移植前经导管动脉栓塞术（TAE）治疗常染色体显性多囊肾病（ADPKD）肿大肾脏的体积缩小：一项系统评价和荟萃分析
Cardiovasc Intervent Radiol. 2018 Jun;41(6):828-834. doi: 10.1007/s00270-018-1890-7. Epub 2018 Jan 31.
8
The Risk for New-Onset Diabetes Mellitus after Kidney Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Meta-Analysis.常染色体显性遗传多囊肾病患者肾移植后新发糖尿病的风险：系统评价和荟萃分析。
Can J Diabetes. 2016 Dec;40(6):521-528. doi: 10.1016/j.jcjd.2016.03.001. Epub 2016 May 13.
9
The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis.托伐普坦治疗常染色体显性遗传性多囊肾病患者的安全性和有效性：一项系统评价和荟萃分析。
Nefrologia (Engl Ed). 2023 Nov-Dec;43(6):731-741. doi: 10.1016/j.nefroe.2023.04.002. Epub 2023 May 5.
10
The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression.疾病严重程度标志物对常染色体显性多囊肾病患者生活质量的影响：一项系统评价、荟萃分析和荟萃回归分析
BMC Nephrol. 2017 May 25;18(1):169. doi: 10.1186/s12882-017-0578-6.
本文引用的文献
1
Overweight Status, Obesity, and Progression to ESKD in Patients with Autosomal Dominant Polycystic Kidney Disease.常染色体显性多囊肾病患者的超重状态、肥胖与终末期肾病进展
Clin J Am Soc Nephrol. 2025 Apr 1;20(4):520-528. doi: 10.2215/CJN.0000000640. Epub 2025 Feb 19.
2
KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary.KDIGO 2025常染色体显性多囊肾病（ADPKD）评估、管理及治疗临床实践指南：执行摘要
Kidney Int. 2025 Feb;107(2):234-254. doi: 10.1016/j.kint.2024.07.010.
3
Visceral Adiposity and Progression of ADPKD: A Cohort Study of Patients From the TEMPO 3:4 Trial.内脏脂肪与常染色体显性多囊肾病的进展：来自TEMPO 3:4试验患者的队列研究
Am J Kidney Dis. 2024 Sep;84(3):275-285.e1. doi: 10.1053/j.ajkd.2024.02.014. Epub 2024 Apr 10.
4
Assessing the Risk of Progression to Kidney Failure in Patients With Autosomal Dominant Polycystic Kidney Disease.评估常染色体显性多囊肾病患者进展为肾衰竭的风险。
Adv Kidney Dis Health. 2023 Sep;30(5):407-416. doi: 10.1053/j.akdh.2023.06.002.
5
Shared pathobiology identifies AMPK as a therapeutic target for obesity and autosomal dominant polycystic kidney disease.共同的病理生物学表明，AMPK是肥胖症和常染色体显性多囊肾病的治疗靶点。
Front Mol Biosci. 2022 Aug 23;9:962933. doi: 10.3389/fmolb.2022.962933. eCollection 2022.
6
Overweight and Obesity and Progression of ADPKD.超重和肥胖与 ADPKD 的进展。
Clin J Am Soc Nephrol. 2021 Jun;16(6):908-915. doi: 10.2215/CJN.16871020. Epub 2021 Jun 11.
7
Insights into Autosomal Dominant Polycystic Kidney Disease from Genetic Studies.常染色体显性遗传性多囊肾病的遗传学研究进展
Clin J Am Soc Nephrol. 2021 May 8;16(5):790-799. doi: 10.2215/CJN.02320220. Epub 2020 Jul 20.
8
Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Evidence and Therapeutic Potential.常染色体显性遗传多囊肾病中的代谢重编程：证据与治疗潜力。
Clin J Am Soc Nephrol. 2020 Apr 7;15(4):577-584. doi: 10.2215/CJN.13291019. Epub 2020 Feb 21.
9
Metabolic reprogramming and the role of mitochondria in polycystic kidney disease.代谢重编程及线粒体在多囊肾病中的作用。
Cell Signal. 2020 Mar;67:109495. doi: 10.1016/j.cellsig.2019.109495. Epub 2019 Dec 6.
10
Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease.超重和肥胖是常染色体显性遗传多囊肾病早期进展的预测因素。
J Am Soc Nephrol. 2018 Feb;29(2):571-578. doi: 10.1681/ASN.2017070819. Epub 2017 Nov 8.
Zotero 插件